Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease

Yuri Tasaka,Takayuki Honda,Naoki Nishiyama,Toshiharu Tsutsui,Hiroaki Saito,Haruna Watabe, Kazuhiro Shimaya, Akifumi Mochizuki,Shun Tsuyuki,Tatsuo Kawahara,Rie Sakakibara,Takahiro Mitsumura,Tsukasa Okamoto,Masayoshi Kobayashi,Tomoshige Chiaki,Takaaki Yamashita,Yoshikazu Tsukada,Reiko Taki,Yasuto Jin,Hiroyuki Sakashita, Ichirou Natsume, Kazuhito Saitou,Yoshihiro Miyashita,Yasunari Miyazaki

Lung Cancer（2021）

引用 24|浏览7

暂无评分

摘要

•A largest cohort including 49 of NSCLC patients with pre-exiting ILD.•The clinical outcomes showed no statistical difference between ILD and Non-ILD group.•Checkpoint inhibitor pneumonitis was more frequently observed in ILD group.•NSCLC patients with ILD could be probable candidates for ICI.

查看译文

关键词

AID,CIP,CR,DCR,IASLC,ICI,ILD,irAE,NSCLC,OS,PD,PD-1,PFS,PR,RR,SD,TKI,TMB,TNM,TPS,UIP

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要